Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Systematic COronary Risk Evaluation (SCORE) and 20-year risk of cardiovascular mortality and cancer

P. Wohlfahrt, J. Bruthans, A. Krajčoviechová, P. Šulc, A. Linhart, J. Filipovský, O. Mayer, J. Widimský, M. Blaha, J. Abrahámová, R. Cífková

. 2020 ; 79 (-) : 63-69. [pub] 20200610

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21012190

Grantová podpora
NV15-27109A MZ0 CEP - Centrální evidence projektů

BACKGROUND: Cardiovascular disease (CVD) followed by cancer are the two leading causes of death worldwide. SCORE charts have been recommended in Europe to identify individuals at increased CVD risk. However, the SCORE ability to identify individuals at increased risk of cancer has not yet been evaluated. The aim of this study was to determine the SCORE chart calibration in a country with changing CVD epidemiology, and its discrimination ability to identify individuals at increased risk of cancer over 20-years. METHODS: The present analysis includes data from two cross-sectional independent surveys within the Czech post-MONICA study (randomly selected representative population samples of the Czech Republic, aged 25-64 years); 3209 individuals in 1997/98 and 3612 in 2006-2009. RESULTS: The SCORE had reasonable discrimination to predict 10-year CVD mortality, but significantly overestimated the risk across all risk categories. During the 20-year follow up, high and very high-risk categories were associated with an increased risk of cancer morbidity (in particular colorectal, other gastrointestinal, lung and malignant skin) and cancer mortality, as compared to low risk category. CONCLUSIONS: The present study shows that periodical calibration testing of SCORE charts is needed in countries with changing CVD epidemiology. Furthermore, we show that in middle-aged individuals, identified by SCORE charts as being at high or very high risk for CVD, cancer morbidity and cancer mortality is increased. Rigorous cancer screening may be appropriate in this group, especially in countries with falling CVD mortality, where relative proportion of cancer mortality is increasing.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21012190
003      
CZ-PrNML
005      
20210507102152.0
007      
ta
008      
210420s2020 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ejim.2020.05.034 $2 doi
035    __
$a (PubMed)32534942
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Wohlfahrt, Peter $u Center for Cardiovascular Prevention, Charles University in Prague, First Faculty of Medicine and Thomayer Hospital, Prague, Czech Republic. Electronic address: wohlfp@gmail.com
245    10
$a Systematic COronary Risk Evaluation (SCORE) and 20-year risk of cardiovascular mortality and cancer / $c P. Wohlfahrt, J. Bruthans, A. Krajčoviechová, P. Šulc, A. Linhart, J. Filipovský, O. Mayer, J. Widimský, M. Blaha, J. Abrahámová, R. Cífková
520    9_
$a BACKGROUND: Cardiovascular disease (CVD) followed by cancer are the two leading causes of death worldwide. SCORE charts have been recommended in Europe to identify individuals at increased CVD risk. However, the SCORE ability to identify individuals at increased risk of cancer has not yet been evaluated. The aim of this study was to determine the SCORE chart calibration in a country with changing CVD epidemiology, and its discrimination ability to identify individuals at increased risk of cancer over 20-years. METHODS: The present analysis includes data from two cross-sectional independent surveys within the Czech post-MONICA study (randomly selected representative population samples of the Czech Republic, aged 25-64 years); 3209 individuals in 1997/98 and 3612 in 2006-2009. RESULTS: The SCORE had reasonable discrimination to predict 10-year CVD mortality, but significantly overestimated the risk across all risk categories. During the 20-year follow up, high and very high-risk categories were associated with an increased risk of cancer morbidity (in particular colorectal, other gastrointestinal, lung and malignant skin) and cancer mortality, as compared to low risk category. CONCLUSIONS: The present study shows that periodical calibration testing of SCORE charts is needed in countries with changing CVD epidemiology. Furthermore, we show that in middle-aged individuals, identified by SCORE charts as being at high or very high risk for CVD, cancer morbidity and cancer mortality is increased. Rigorous cancer screening may be appropriate in this group, especially in countries with falling CVD mortality, where relative proportion of cancer mortality is increasing.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    12
$a kardiovaskulární nemoci $x epidemiologie $7 D002318
650    _2
$a průřezové studie $7 D003430
650    _2
$a lidé $7 D006801
650    _2
$a lidé středního věku $7 D008875
650    12
$a nádory $x epidemiologie $7 D009369
650    _2
$a hodnocení rizik $7 D018570
650    _2
$a rizikové faktory $7 D012307
651    _2
$a Česká republika $7 D018153
651    _2
$a Evropa $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Bruthans, Jan $u Center for Cardiovascular Prevention, Charles University in Prague, First Faculty of Medicine and Thomayer Hospital, Prague, Czech Republic
700    1_
$a Krajčoviechová, Alena $u Center for Cardiovascular Prevention, Charles University in Prague, First Faculty of Medicine and Thomayer Hospital, Prague, Czech Republic
700    1_
$a Šulc, Pavel $u Center for Cardiovascular Prevention, Charles University in Prague, First Faculty of Medicine and Thomayer Hospital, Prague, Czech Republic
700    1_
$a Linhart, Aleš $u Department of Medicine II, Charles University in Prague, First Faculty of Medicine, Prague, Czech Republic
700    1_
$a Filipovský, Jan $u Department of Medicine II, Faculty of Medicine, Charles University,Pilsen, Czech Republic
700    1_
$a Mayer, Otto $u Department of Medicine II, Faculty of Medicine, Charles University,Pilsen, Czech Republic
700    1_
$a Widimský, Jiří $u Department of Medicine III, Charles University in Prague, First Faculty of Medicine, Prague, Czech Republic
700    1_
$a Blaha, Milan $u Institute of Health Information and Statistics of the Czech Republic, Prague, Czech Republic
700    1_
$a Abrahámová, Jitka $u Proton Therapy Center, Prague, Czech Republic
700    1_
$a Cífková, Renata $u Center for Cardiovascular Prevention, Charles University in Prague, First Faculty of Medicine and Thomayer Hospital, Prague, Czech Republic; Department of Medicine II, Charles University in Prague, First Faculty of Medicine, Prague, Czech Republic
773    0_
$w MED00001627 $t European journal of internal medicine $x 1879-0828 $g Roč. 79, č. - (2020), s. 63-69
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32534942 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210420 $b ABA008
991    __
$a 20210507102151 $b ABA008
999    __
$a ok $b bmc $g 1650544 $s 1132569
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 79 $c - $d 63-69 $e 20200610 $i 1879-0828 $m European journal of internal medicine $n Eur J Intern Med $x MED00001627
GRA    __
$a NV15-27109A $p MZ0
LZP    __
$a Pubmed-20210420

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace